Nabsys, the pioneer in electronic whole-genome mapping, announced the appointment of Kevin DeGeeter as Chief Financial Officer.
Latest Fintech News: M&T Bank Names Dominique Goss Executive Director of M&T Charitable Foundation
“I am excited to welcome Kevin to the executive team,” said Barrett Bready, MD, Nabsys Founder and CEO. “Kevin’s deep understanding of the genomics space, as well as his reputation among investors and operators as an important source of tools and diagnostics knowledge and analysis, will be important assets.”
Kevin DeGeeter has over two decades of buy- and sell-side equity research experience evaluating life science tools and biotechnology companies. He joins Nabsys from Oppenheimer & Co Inc. where he served as Managing Director and Senior Equity Research Analyst for Diagnostics & Biotechnology. Previously he worked at J.P Morgan, Paine Webber, Ladenburg Thalmann and Manning & Napier Advisors.
Latest Fintech News: Nickel Digital Arbitrage Fund Cuts Crypto Volatility by More Than 20X
Michael Margolis, Head of Oppenheimer’s leading Life Science Investment Banking practice, commented “We are looking forward to engaging with Kevin in his new role at Nabsys as we continue to focus on this very important segment of the Life Science space. Investor interest in Tools and Diagnostics is growing rapidly as recognition for the important innovations that are being made continue to enhance the potential for lifesaving diagnostics and treatments.”
John Parks, Director of Research for Oppenheimer commented, “Over his six years as a core member of Oppenheimer’s highly regarded Life Science / Biotechnology research team, Kevin has been a strong advocate for deep and thorough coverage of the most important companies in Tools and Diagnostics. His expertise has been a valuable contribution to Oppenheimer’s successful leadership in generating investor interest in the companies that lead research and development for this important area of life sciences.”
“There remains important unmet need for new technologies to assess structural variants and other genomic analysis not served by short read sequencing,” noted Kevin DeGeeter. “I believe electronic whole-genome mapping offers the promise of better resolution with lower cost than alternative modalities and look forward to supporting the Nabsys team and global strategic partners to bring electronic whole-genome mapping to researchers and eventually tapping the clinical diagnostics market.”
Latest Fintech News: Supermojo Announces Completion of Seed Round to Streamline NFT Access
[To share your insights with us, please write to sghosh@martechseries.com]
